203
Views
4
CrossRef citations to date
0
Altmetric
Research Articles

Mining of potential dipeptidyl peptidase-IV inhibitors as anti-diabetic agents using integrated in silico approaches

, , , , , , , , & show all
Pages 5349-5361 | Received 28 Aug 2019, Accepted 25 Nov 2019, Published online: 18 Dec 2019
 

Abstract

The dipeptidyl peptidase-IV (DPP-IV) family of receptors possesses a large binding cavity that imparts promiscuity for number of ligand binding which is not common to other receptors. This feature increases the challenge of using computational methods to identify DPP-IV inhibitors, therefore using both pharmacophore and structure-based screening seems to be a reliable approach. Mining of novel DPP-IV inhibitors by integrating both of these in silico techniques was reported. Pharmacophore model (Model_008) obtained from structurally diverse reported compounds was used as a template for screening of MolMall database followed by structure-based screening against PDB ID: 5T4E. After absorption, distribution, metabolism and excretion (ADME) analysis of shortlisted compounds, consensus docking and molecular mechanics/generalized born surface area studies were carried out. The results of the docking studies obtained were comparable to that of the reference ligand. Out of nine hits identified, only one hit (ID MolMall-20062) was available which was procured through exchange program. Molecular dynamic simulation studies of the procured hit revealed its good selectivity and stability in DPP-IV binding pocket and interactions observed with important amino acids viz., Trp629, Lys544 and Arg125. Biological testing of the compound MolMall-20062 showed promising DPP-IV inhibition activity with IC50: 6.2 µM. Compound MolMall-20062 could be taken as a good lead for the development of DPP-IV inhibitors.

Abbreviations
ADME=

absorption, distribution, metabolism and excretion

ChEBI=

chemical entities of biological interest

DPP-IV=

dipeptidyl peptidase IV

DISCOtech=

distance comparisons

HTVS=

high throughput virtual screening

MD=

molecular dynamics

MM-GBSA=

molecular mechanics‐generalized born surface area

OGTT=

oral glucose tolerance test

PBVS=

pharmacophore-based virtual screening

PDB=

protein data bank

RMSD=

root mean square deviation

ROC=

receiver operating characteristics

SP=

standard precision

SBVS=

structure-based virtual screening

VS=

virtual screening

XP=

extra precision

Communicated by Ramaswamy H. Sarma

Acknowledgements

Authors are grateful to the Department of Biotechnology, New Delhi, India for providing BIF facility (via letter no. AS/MP (RES)/JH-5/2013) and Vice Chancellor, Jamia Hamdard for other facilities and support.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This paper was supported by the Department of Biotechnology, Ministry of Science and Technology, New Delhi, India.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.